SERPINA1
EstablishedSERPINA1/AAT deficiency is an underdiagnosed genetic cause of early COPD and liver disease, per a newly updated 2024/2025 guideline.
This gene makes a protein that protects the lungs. When someone doesn't make enough of it, they're at risk for early lung and liver disease, even without smoking, though smoking makes it much worse. A weekly infusion treatment exists, but it's currently reserved for the most severe cases.
SERPINA1 encodes alpha-1 antitrypsin (AAT), a protein that protects lung tissue from enzymatic damage; its genetic deficiency is an underdiagnosed cause of early-onset COPD and liver disease.
Low AAT levels, combined with genotyping (most severe deficiency from the ZZ genotype), confirm alpha-1 antitrypsin deficiency (AATD), which increases risk of emphysema (especially in smokers) and can independently cause liver cirrhosis.
A 2024/2025 Canadian Thoracic Society guideline update (published in CHEST) refined testing and treatment recommendations for this condition, emphasizing targeted testing of at-risk populations (early-onset COPD, unexplained liver disease, family history) using modern genetic testing methods.
Current guidelines generally restrict IV augmentation therapy (weekly infusions of human AAT) to severe deficiency with functional lung impairment, not milder "intermediate" deficiency, even though some emerging retrospective data suggest possible benefit in select intermediate-deficiency patients with significant respiratory symptoms.
Augmentation therapy is currently restricted to severe deficiency, though evidence for intermediate-deficiency patients is emerging.
- CHEST. (2025). Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-analysis and Clinical Practice Guideline.
- PMC. (2025). Phenotypic Expression of Respiratory Diseases in Patients with Intermediate Alpha-1 Antitrypsin Deficiency.